GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDING CO., LTD.

Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.

874 CNE100000387

Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. specializes in researching, developing and manufacturing pharmaceutical products. The group's products include analgesics, antibiotics, medicines for the treatment of stomach disorders, treatment of cough, antitoxic products, etc.

Sector

Pharmaceuticals

Calendar

2024-04-26 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18.95 CNY

Average target price

22.06 CNY

Spread / Average Target

+16.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDING CO., LTD.	-5.75%	6.7B
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:09:13 2024-04-23 am EDT			5-day change	1st Jan Change
20.5 ^HKD	-0.24%		+4.49%	-5.75%

Mar. 18	Baiyunshan Pharmaceutical's 2023 Profit Rises 2%	MT
Mar. 15	Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Announces Final Ordinary Dividend for the Year Ended 31 December 2023	CI

Baiyunshan Pharmaceutical's 2023 Profit Rises 2%	Mar. 18	MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Announces Final Ordinary Dividend for the Year Ended 31 December 2023	Mar. 15	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Baiyunshan Pharma's Unit Gets Green Light to Produce Hepatitis B Drug	Mar. 01	MT
Guangzhou Pharma Unit Gets Green Light to Trial Oral Liquid Drug	Feb. 09	MT
Guangzhou Baiyunshan Pharmaceutical Arm Floats 1 Billion Yuan Biomedical VC Fund	Dec. 19	MT
Guangzhou Baiyunshan Pharmaceutical Ends Spin-Off Plans, Seeks China Listing for Subsidiary	Dec. 19	MT
Guangzhou Pharma Expands Scope of Drug Production License	Nov. 13	MT
Guangzhou Baiyunshan Pharmaceutical's Profit Up 11% in Q3	23-10-30	MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Baiyunshan Pharmaceutical Reports Increase in H1 Attributable Profit	23-09-13	MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(SHSE:600332) added to Shanghai Stock Exchange 180 Value Index	23-06-12	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(SHSE:600332) added to SSE 180 Index	23-06-12	CI
Guangzhou Pharma Registers Pain-Relief, Anti-Inflammatory Drugs in Russia	23-05-26	MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 30, 2023	23-04-27	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Announces Election of the Supervisor Representing the Employees of the 9th Session of the Supervisory Committee	23-04-25	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Announces Final Dividend for the Year Ended 31 December 2022	23-03-17	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
Baiyunshan Pharma to Inject 334 Million Yuan Into New Fund	23-03-02	MT
Baiyunshan Pharma Gets Nod for Tablets for Male Patients	23-01-09	MT
Baiyunshan Pharma Gets Regulatory Nod for Dapoxetine Hydrochloride	22-12-20	MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited completed the acquisition of stake in Guangzhou Pharmaceuticals Corporation from Alliance Bmp Limited.	22-12-14	CI
Baiyunshan Pharmaceutical to Raise $420.5 Million Through Asset Disposal	22-11-22	MT
Guangzhou Baiyunshan Eyes Offering of $420 Million Renminbi Bonds	22-11-22	MT

Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.

Equities

874

CNE100000387